• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 5th June 2019

OHE at the 2019 Spanish Health Economics Association (AES) Conference

Meet some of the OHE team at the Spanish Health Economics Association (AES) 2019 conference in Albacete, 12-14 June. Meet some of the OHE team at the Spanish Health Economics Association (AES) 2019 conference in Albacete, 12-14 June. The 39th…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Meet some of the OHE team at the Spanish Health Economics Association (AES) 2019 conference in Albacete, 12-14 June.

Meet some of the OHE team at the Spanish Health Economics Association (AES) 2019 conference in Albacete, 12-14 June.

The 39th AES conference will take place from 12th to 14th June in Albacete, with the theme Transparency is healthy. The importance of accountability in healthcare. Bernarda Zamora, Maria Errea, Marina Rodes Sanchez, and Patricia Cubí-Mollá will all be attending the conference, presenting work from OHE’s ongoing research studies.

Organised Session I: The introduction of pay for performance for specialised care in England

Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina will describe the key features of the schemes and discuss its strengths and weaknesses based on international pay-for-performance literature. The session is organized by Patricia, joint with Laia Maynou (London School of Economics), on behalf of the special interest group on the evaluation of health policies and health care services (EvaluAES).

Communications Panels V, O-24: Quantifying the life-cycle value of innovative medicines: the case of risperidone and second-generation antipsychotics

This study, co-authored by Mikel Berdud, Bernarda Zamora, and Adrian Towse, aims to guide access decisions and drive the discussion on access and price, through recognition of the dynamic nature of value added by pharmaceutical innovation over the long-run. The analysis of the life-cycle value of risperidone estimates the value generated in the UK and Sweden. Results show that health systems were able to appropriate most of the life-cycle value generated, and this is larger than estimated at launch.

Communications Panels VIII, O-37: Outcome-based payment schemes: what outcomes do cancer patients value?

One way to improve access to new cancer medicines in England is to introduce more flexible pricing mechanisms. This reflects a growing interest in alternative forms of pharmaceutical pricing arrangements, where the effectiveness of a drug, in an indication or a (sub)population, remains uncertain despite trial evidence. One of the alternatives that is gaining traction is outcome-based payment (OBP), whereby the price paid for the drug is linked to the real-world outcomes it achieves for patients. In general, OBP schemes have focused on clinical outcomes. However, it is unclear which outcomes cancer patients value most. Patricia will present the main results of a project funded by Cancer Research UK with Greater Manchester Health & Social Care Partnership, on Making Outcome-based payments a reality in the NHS. The authors found that the most important outcomes to patients and carers are survival; progression, relapse or recurrence; long-term side effects; and return to normal activities. Notably, only mortality is routinely collected within the NHS, progression and morbidity data exist but are not currently linked, creating a challenge for OBP.

Communications Panels XVI, O-73: A multinational European study of patient preferences for novel diagnostics to tackle antimicrobial resistance

Novel diagnostics are needed to tackle antimicrobial resistance (AMR). Patient preferences are important in determining whether diagnostic tests are successful in practice, but there is little evidence around what matters most to patients. We used a discrete choice experiment to elicit patients’ preferences for attributes of diagnostic tests across seven European countries. Responses from Germany and the Netherlands indicated that confidence in the test result is of the highest importance; responses from the UK, France, Spain, and Italy showed convenience as the most important attribute. Confidence and convenience were jointly favoured by respondents in Greece. Time until results are available was the least important attribute in most countries. This presentation will be given by OHE Visiting Fellow, Jorge Mestre-Ferrandiz.

Poster session IV, P-51: Blood donation in the UK. Are we doing all right or could we do better?

Blood is collected in the UK through voluntary (not remunerated) human donations. The number of appointments booked with NHS Blood and Transplant (NHSBT) has significantly risen in recent years. However, evidence shows that the number of appointments is greater than the number of final blood donations. Given that there is an urgent need for more blood donors, NHSBT is interested to explore the key factors that are driving potential donors who book an appointment to make a blood donation (or not). The aim of this project is to explore the circumstances and characteristics that lead to a donation, compared to those that do not lead to a donation, amongst people who book an appointment. For this poster presentation, Maria will discuss previous research showing that campaigns have an impact on the number of new blood donors, and consider data on the number of new donors per day compared with the level of demand in NHSBT.

Invited session VI: Experiencia docente en la organización y gestión de servicios sanitarios

In this session, Maria will contribute to a discussion of experiences in delivering a postgraduate course – launched two years ago – for current professionals of the health care system who want to become managers of a health organisation. Maria has been part of the team of coordinators, with the responsibility for coordinating two key modules (of a 10-module course). The presentation will be about the experience of teaching to a very particular group of students, most of whom work full time at a hospital or ambulatory health care centre, and about the organisation of the modules.

  • Research
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!